Celiac disease: a model autoimmune disease with gene therapy applications
Celiac disease: a model autoimmune disease with gene therapy applications
Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.
835-843
Londei, M.
2d82e120-d610-4bb3-9f93-441ee4c7d419
Quaratino, S.
e111fc36-bc7e-461b-996d-849e97c51e44
Maiuri, L.
11e256c3-912e-4479-b19d-1f64e4f2fd46
2003
Londei, M.
2d82e120-d610-4bb3-9f93-441ee4c7d419
Quaratino, S.
e111fc36-bc7e-461b-996d-849e97c51e44
Maiuri, L.
11e256c3-912e-4479-b19d-1f64e4f2fd46
Londei, M., Quaratino, S. and Maiuri, L.
(2003)
Celiac disease: a model autoimmune disease with gene therapy applications.
Gene Therapy, 10 (10), .
(doi:10.1038/sj.gt.3302041).
Abstract
Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.
This record has no associated files available for download.
More information
Published date: 2003
Identifiers
Local EPrints ID: 26440
URI: http://eprints.soton.ac.uk/id/eprint/26440
PURE UUID: 48169105-4905-4b4a-9735-3bfe1ee56212
Catalogue record
Date deposited: 19 Apr 2006
Last modified: 15 Mar 2024 07:10
Export record
Altmetrics
Contributors
Author:
M. Londei
Author:
S. Quaratino
Author:
L. Maiuri
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics